New England Journal of Medicine· 2022Q1
Two Phase 3 Trials of Baricitinib for Alopecia Areata
- 471citations
- Q1SCImago
- 2022year
Short summary
In two Phase 3 trials (n=1200), 4-mg oral baricitinib achieved significant hair regrowth in severe alopecia areata patients, with 38.8% (BRAVE-AA1) and 35.9% (BRAVE-AA2) reaching a SALT score of <=20 at 36 weeks, compared to 6.2% and 3.3% for placebo.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Urology
UrologyMedicine